VESCO-R®: Peripheral Blood Derived Mesenchymal Stem Cell Therapy in Regenerative Medicine

点击翻译按钮获取中文摘要

Cell therapies offer the opportunity to treat and cure serious unmet medical needs. BioDivide has discoveredan innovative manufacturing technology to develop VESCO-R® - a suspension of autologous Mesenchymal StemCells (MSCs) derived from a limited peripheral blood sample. Current state-of-the-art processes to isolate MSCsfrom peripheral blood are highly inefficient and variable. The Company screened >500 conditions to developthe underpinning science for this break-through technology. Current autologous stem cell biopsy techniquesrequire invasive surgical procedures (e.g. bone marrow and adipose tissue harvesting under generalanaesthetic). Peripheral blood donation is minimally invasive and would overcome significant barriers to theindustry. BioDivide, in collaboration with Genesis, is seeking Innovate UK Funding to enable the translation ofthis technology from the bench to a market-ready manufacturing process and the therapeutic product, VESCO-R®. BioDivide envisions transforming regenerative medicine by initially validating VESCO-R® for musculoskeletaldisorders in veterinary medicine with the ultimate aim to translate this technology to human health.blic Project Summary